Jump to top navigation | Jump to main navigation | Jump to content
Therapeutic Goods Administration logo

NDPSC record of reasons, 46th meeting, 21-23 February 2006

National Drugs and Poisons Schedule Committee

The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

NDPSC Record of reasons, Meeting 46 (pdf,592kb)*

Contents

Glossary
  • 1.8 NDPSC working parties
    • 1.8.1 Trans-Tasman Harmonisation Working Party
      • 1.8.1.2 Substances Identified in the OZNZ Scheduling Database as Unharmonised
        • 1.8.1.2.1 Aconitum SPP
        • 1.8.1.2.2 Acrivastine, Amidopyrine and Atosiban
        • 1.8.1.2.3 Amorolfine
        • 1.8.1.2.4 Amphotericin
        • 1.8.1.2.5 Antimony organic compounds
        • 1.8.1.2.6 Aspirin
        • 1.8.1.2.7 Atropa belladonna and Hyoscyamus niger
        • 1.8.1.2.8 Beclomethasone and Budesonide
        • 1.8.1.2.9 Boron/Boric acid
        • 1.8.1.2.10 Camphorated oil
        • 1.8.1.2.11 Cathine
        • 1.8.1.2.12 Cephacetrile, Cephaloridine, Cephamandole and Cephapirin
        • 1.8.1.2.13 Cephazolin
        • 1.8.1.2.14 Dibrompropamidine and Propamidine
        • 1.8.1.2.16 Mercury organic compounds
        • 1.8.1.2.17 Pirfenoxone sodium (Catalin)
        • 1.8.1.2.18 Blood products
      • 1.8.2.1 Outcomes of the TTHWP Meeting 15 (Cyclizine and Recombinant Medicines Nomenclature)
        • 1.8.2.1.1 Cyclizine
        • 1.8.2.1.2 Recombinant medicines

Top of page

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons
  • 2.1 SUSDP, Part 1
  • 2.2 SUSDP, Part 2
    • 2.2.1 Approved name for Amines used as curing agents for epoxy resins
    • 2.2.2 Storage Statements for Schedule 5 and 6 products
Agricultural/Veterinary, Industrial and Domestic Chemicals
3. Matters arising from the minutes of the previous meeting
4. Other outstanding matters from previous meetings
  • 4.1 Paraquat
  • 4.2 Alkaline salts
    • 4.2.1 Lye water
  • 4.3 Chlorhexidine
5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons
  • 5.1 SUSDP, Part 4
    • 5.1.1 Cysteamine hydrochloride
    • 5.1.2 Sodium polystyrene sulphonate

Top of page

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority
  • 6.1 Prohexadione calcium
  • 6.2 Florasulam
  • 6.3 Amicarbazone
7. Matters referred by Office of Chemical Safety (OCS) Branch
  • 7.1 Industrial biocides
Pharmaceuticals
10. Matters arising from the minutes of the previous meeting
  • 10.1 Phenylephrine
  • 12.2 Paracetamol
11. Other outstanding matters from previous meetings
  • 11.1 Pseudoephedrine
  • 11.2 Sedating antihistamines (Brompheniramine, Chlorpheniramine, Dexchlorpheniramine, Diphenylpyraline, Doxylamine, Pheniramine, Thenyldiamine, Trimeprazine, Triprolidine)
    • 11.2.1 Sedating antihistamines in travel sickness products (Cyclizine, Dimenhydrinate, Diphenhydramine, Meclozine and Promethazine)
  • 11.3 Amisulpride
  • 11.4 Blood products
    • 11.4.1 Octocog alfa
    • 11.4.2 Human plasma-derived protein C
  • 11.5 Definition of compounded
  • 11.6 Pantoprazole

Top of page

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons
  • 12.1 SUSDP, Part 4
    • 12.1.1 Ketotifen
    • 12.1.2 Azelastine hydrochloride
    • 12.1.3 Ibuprofen (400 mg tablet)
    • 12.1.4 Clotrimazole
    • 12.1.5 Codeine - Consideration of the scheduling of liquid preparations containing Codeine as a single active ingredient
    • 12.1.6 Potassium chloride
    • 12.1.7 Levonorgestrel
  • 12.2 SUSDP, Part 5
    • 12.2.1 Orlistat
    • 12.2.2 Item deleted
    • 12.2.3 Cetirizine

Top of page

13. Matters referred by the Australian Drug Evaluation Committee (ADEC)
  • 13.1 New substances (not seen before by the NDPSC)
    • 13.1.1 Palifermin
    • 13.1.2 Rasagiline
    • 13.1.3 Olmesartan medoxomil
    • 13.1.4 Lanthanum carbonate
    • 13.1.5 Pegvisomant
14. Other matters for consideration
  • 14.1 Item deleted
  • 14.2 Benzylpiperazine and Trifluoromethylphenylpiperazine
16. Matters referred by the medicines classification committee (MCC) of New Zealand
  • 16.1 November 2004 and June 2006 MCC meetings
    • 16.1.1 Nasal corticosteroid preparations (Fluticasone, Beclomethasone, Budesonide, Mometasone and Triamcinolone)
    • 16.1.2 Mepyramine, Oxiconazole and Schoenocaulon officinale (Sabadilla)
      • 16.1.2.1 Mepyramine
      • 16.1.2.2 Oxiconazole
      • 16.1.2.3 Schoenocaulon officinale (Sabadilla)
    • 16.1.3 New S4 medicines (Fulvestrant, Palonosetron, Terlipressin, Alemtuzumab, Anecortave, Entecavir, Erlotinib, Muraglitazar, Nesiritide, Pegaptanib, Posaconazole and Solifenacin)
17. Item deleted
18. Matters referred by the Medical Devices Evaluation Committee (MDEC)
19-20. Items deleted
21. Amendments to the SUSDP
  • 21.1 Editorial changes and errata
    • 21.1.1 Nomenclature for certain cephalosporin antibiotics (Cephaloridine, Cephacetrile, Cephamandole, Cephapirin and Cephazolin)
    • 21.1.2 Nomenclature of Pirfenoxone sodium (Catalin)
    • 21.1.3 Nicotine

Top of page